---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-027007"
form_type: "8-K"
ticker: "FATE"
cik: "0001434316"
company_name: "FATE THERAPEUTICS INC"
filed_at: "2023-06-08T23:59:59+00:00"
generated_at: "2026-06-14T04:52:04.706374+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Fate Therapeutics CMO Dr. Wayne Chu resigns effective July 14, 2023

## Summary
- Dr. Yu-Waye (Wayne) Chu, Chief Medical Officer, resigns to pursue another opportunity.
- Resignation effective July 14, 2023; no disagreement with company operations or policies.
- No replacement named; CEO J. Scott Wolchko signed the filing.

## SEC filing metadata
- accession: 0000950170-23-027007
- form_type: 8-K
- ticker: FATE
- cik: 0001434316
- company_name: FATE THERAPEUTICS INC
- filed_at: 2023-06-08T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434316/000095017023027007/0000950170-23-027007-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434316/000095017023027007/fate-20230608.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-027007
- JSON: https://secwatch.observer/filing/0000950170-23-027007.json
- Plain text: https://secwatch.observer/filing/0000950170-23-027007.txt

## Key facts
- Executive change
  Yu-Waye (Wayne) Chu departed as Chief Medical Officer at FATE THERAPEUTICS INC.
  - Action: resign
  - Role: Chief Medical Officer
  source text: Dr. Yu-Waye (Wayne) Chu, M.D. notified Fate Therapeutics, Inc. (the “Company”) that he intends to resign as Chief Medical Officer of the Company effective as of July 14, 2023 to pursue another opportunity.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434316/000095017023027007/0000950170-23-027007-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.